NASDAQ:SUPN

Supernus Pharmaceuticals Stock Forecast, Price & News

$27.26
+0.44 (+1.64 %)
(As of 09/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.85
$27.38
50-Day Range
$23.54
$28.02
52-Week Range
$17.20
$34.29
Volume150,742 shs
Average Volume499,748 shs
Market Capitalization$1.45 billion
P/E Ratio14.74
Dividend YieldN/A
Beta1.22
30 days | 90 days | 365 days | Advanced Chart
Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Supernus Pharmaceuticals logo

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.19 out of 5 stars

Medical Sector

358th out of 1,352 stocks

Pharmaceutical Preparations Industry

174th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

Is Supernus Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Supernus Pharmaceuticals stock.
View analyst ratings for Supernus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Supernus Pharmaceuticals?

Wall Street analysts have given Supernus Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Supernus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Supernus Pharmaceuticals
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings results on Wednesday, August, 4th. The specialty pharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.17 by $0.26. The specialty pharmaceutical company had revenue of $141.33 million for the quarter, compared to the consensus estimate of $135.50 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 13.39% and a net margin of 17.55%. The firm's quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.65 earnings per share.
View Supernus Pharmaceuticals' earnings history
.

How has Supernus Pharmaceuticals' stock price been impacted by COVID-19?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SUPN stock has increased by 68.8% and is now trading at $27.26.
View which stocks have been most impacted by COVID-19
.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $550 million-$580 million, compared to the consensus revenue estimate of $558.02 million.

What price target have analysts set for SUPN?

2 Wall Street analysts have issued 1 year target prices for Supernus Pharmaceuticals' shares. Their forecasts range from $35.00 to $40.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $37.50 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Jack A. Khattar, President, CEO, Secretary & Director
  • Timothy C. Dec, Chief Financial Officer & Senior Vice President
  • Frank Mottola, Senior VP-Quality, GMP Operations & IT
  • Padmanabh P. Bhatt, Chief Scientific Officer & Senior Vice President
  • Jonathan Rubin, Chief Medical Officer & Senior Vice President

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals CEO Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among Supernus Pharmaceuticals' employees.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.32%), Armistice Capital LLC (6.25%), Dimensional Fund Advisors LP (4.28%), Macquarie Group Ltd. (4.02%), Renaissance Technologies LLC (2.85%) and Stephens Investment Management Group LLC (2.35%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends for Supernus Pharmaceuticals
.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, LSV Asset Management, Renaissance Technologies LLC, Ashford Capital Management Inc., Rice Hall James & Associates LLC, Armistice Capital LLC, Hussman Strategic Advisors Inc., and Marshall Wace LLP. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Stefan KF Schwabe, and Tami Tillotson Martin.
View insider buying and selling activity for Supernus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was purchased by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Victory Capital Management Inc., Fuller & Thaler Asset Management Inc., International Biotechnology Trust PLC, Nuveen Asset Management LLC, Dimensional Fund Advisors LP, First Trust Advisors LP, and Stephens Investment Management Group LLC.
View insider buying and selling activity for Supernus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $27.26.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals has a market capitalization of $1.45 billion and generates $520.40 million in revenue each year. The specialty pharmaceutical company earns $126.95 million in net income (profit) each year or $2.36 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals employs 563 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

Where are Supernus Pharmaceuticals' headquarters?

Supernus Pharmaceuticals is headquartered at 1550 E GUDE DR, ROCKVILLE MD, 20850.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at (301) 838-2500 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.